Next Article in Journal
Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis
Previous Article in Journal
Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma
Previous Article in Special Issue
Insight into the Development of PET Radiopharmaceuticals for Oncology
Open AccessReview

Hypoxia PET Imaging with [18F]-HX4—A Promising Next-Generation Tracer

1
The D-Lab and The M-Lab, Department of Precision Medicine, GROW—School for Oncology, Maastricht University, 6211 Maastricht, The Netherlands
2
Department of Radiology and Nuclear Medicine, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Centre+, 6229 Maastricht, The Netherlands
3
Division of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, Hospital Center Universitaire De Liege, 4030 Liege, Belgium
4
Department of Nuclear Medicine and Comprehensive Diagnostic Center Aachen (CDCA), University Hospital RWTH Aachen University, 52074 Aachen, Germany
*
Author to whom correspondence should be addressed.
Indicates equal contribution.
Cancers 2020, 12(5), 1322; https://doi.org/10.3390/cancers12051322
Received: 30 April 2020 / Revised: 18 May 2020 / Accepted: 19 May 2020 / Published: 22 May 2020
(This article belongs to the Special Issue Cancer Molecular Imaging)
Hypoxia—a common feature of the majority of solid tumors—is a negative prognostic factor, as it is associated with invasion, metastasis and therapy resistance. To date, a variety of methods are available for the assessment of tumor hypoxia, including the use of positron emission tomography (PET). A plethora of hypoxia PET tracers, each with its own strengths and limitations, has been developed and successfully validated, thereby providing useful prognostic or predictive information. The current review focusses on [18F]-HX4, a promising next-generation hypoxia PET tracer. After a brief history of its development, we discuss and compare its characteristics with other hypoxia PET tracers and provide an update on its progression into the clinic. Lastly, we address the potential applications of assessing tumor hypoxia using [18F]-HX4, with a focus on improving patient-tailored therapies. View Full-Text
Keywords: molecular imaging; tumor hypoxia; positron emission tomography (PET); [18F]-HX4; theranostics; response assessment molecular imaging; tumor hypoxia; positron emission tomography (PET); [18F]-HX4; theranostics; response assessment
Show Figures

Figure 1

MDPI and ACS Style

Sanduleanu, S.; Wiel, A.M.; Lieverse, R.I.; Marcus, D.; Ibrahim, A.; Primakov, S.; Wu, G.; Theys, J.; Yaromina, A.; Dubois, L.J.; Lambin, P. Hypoxia PET Imaging with [18F]-HX4—A Promising Next-Generation Tracer. Cancers 2020, 12, 1322.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop